CJC-1295 No DAC 5mg (10 vials/kit): Tetrasubstituted Growth Hormone Releasing Hormone Analog

CJC-1295 No DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is a synthetic 29-amino-acid tetrasubstituted peptide analog of human growth hormone-releasing hormone ($\text{GHRH}_{1-29}$). Exhibiting the chemical sequence $\text{Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH}_2$, CJC-1295 No DAC incorporates four specific amino acid substitutions at positions 2, 8, 15, and 27 ($\text{D-Ala}^2$, $\text{Gln}^8$, $\text{Ala}^{15}$, and $\text{Leu}^{27}$). These structural modifications significantly enhance enzymatic stability against dipeptidyl peptidase IV ($\text{DPP-IV}$) cleavage compared to native GHRH and Sermorelin. Sourcing CJC-1295 No DAC 5mg (10 vials/kit) provides neuroendocrinologists, cell biologists, and preclinical research facilities with a high-purity analytical reagent engineered to investigate pituitary somatotroph receptor kinetics, pulsatile growth hormone release, and growth axis regulation.

In physiological and endocrinological research, CJC-1295 No DAC is critical for studying physiological, pulsatile growth hormone ($\text{GH}$) secretion. Unlike its counterpart CJC-1295 WITH DAC (Drug Affinity Complex)—which contains a maleimido-propionic acid linker that binds covalently to circulating serum albumin to extend plasma half-life to several days—CJC-1295 No DAC lacks the affinity complex. Consequently, CJC-1295 No DAC exhibits a distinct half-life profile of approximately 30 minutes. This extended window relative to native GHRH (~8–12 minutes) allows researchers to stimulate sharp, acute GH spikes that closely mimic endogenous physiological release pulses without causing continuous baseline GH elevation (“GH bleed”) or somatotroph receptor desensitization.

Maintaining consistent chemical purity and preventing enzymatic degradation is critical for quantitative receptor-binding assays and secretagogue kinetics. The CJC-1295 No DAC 5mg (10 vials/kit) configuration supplies a total yield of 50mg active peptide material (5mg per vial) distributed across ten individual USP Type I borosilicate glass vials. Freeze-dried under sterile vacuum conditions, each vial contains a uniform, highly stable lyophilized powder cake. This multi-vial kit structure enables laboratory personnel to reconstitute only the active working volume required for immediate experimental runs, keeping remaining kit stock preserved in deep freeze stasis to eliminate structural loss caused by repeated freeze-thaw cycles.

GHRH Receptor Agonism, Enzymatic Resistance, and Technical Profile

The primary scientific value of CJC-1295 No DAC 5mg (10 vials/kit) stems from its high structural stability and selective interaction with pituitary GHRH receptors:

• Tetrasubstituted Stability Modification: Specific amino acid substitutions ($\text{D-Ala}^2$, $\text{Gln}^8$, $\text{Ala}^{15}$, $\text{Leu}^{27}$) shield the peptide backbone from rapid enzymatic degradation by circulating endopeptidases and $\text{DPP-IV}$.

• Pulsatile GH Secretion Profile: Triggers natural, physiological spikes in pituitary growth hormone release without disrupting baseline homeostatic control mechanisms or causing continuous non-pulsatile elevation.

• Pituitary GHRH-R Agonism: Binds with high affinity to GHRH receptors on anterior pituitary somatotrophs, activating adenylate cyclase and increasing intracellular cyclic adenosine monophosphate ($\text{cAMP}$) levels.

• Synergistic Co-Activation Research: Widely utilized in preclinical bioassays alongside Ghrelin/Growth Hormone Secretagogue Receptor ($\text{GHSR}$) agonists (such as Ipamorelin or GHRP-6) to investigate dual-pathway additive GH secretion dynamics.

• Ultra-High Chemical Purity ($\ge$99.0%): Manufactured via automated Solid-Phase Peptide Synthesis ($\text{SPPS}$) and purified using preparative High-Performance Liquid Chromatography ($\text{HPLC}$) to ensure complete removal of deletion sequences and synthesis byproducts.

Reconstitution Guidelines, Laboratory Storage Standards, and Quality Protocols

Achieving reproducible, publication-grade results when working with CJC-1295 No DAC 5mg (10 vials/kit) requires strict adherence to standardized aseptic reconstitution and climate-controlled storage procedures.

Perform all reconstitution procedures inside a certified Class II Biosafety Cabinet:

1. Temperature Equilibration: Allow the frozen CJC-1295 No DAC vial to adjust to ambient room temperature prior to solvent introduction to eliminate moisture condensation inside the glass container.

2. Septum Sanitization: Remove the protective plastic flip-cap and thoroughly wipe the synthetic rubber stopper with a fresh 70% isopropyl alcohol pad. Allow the surface to air-dry completely.

3. Slow Diluent Addition: Using a sterile syringe equipped with a fine-gauge needle, draw the required volume of Bacteriostatic Water (0.9% benzyl alcohol), Sterile Normal Saline (0.9% NaCl), or Phosphate-Buffered Saline (PBS). Direct the liquid stream against the inner glass wall so it trickles slowly over the lyophilized cake.

4. Gentle Hydration: Allow the diluent to fully hydrate the powder cake for 2 minutes. Gently roll the vial between your palms or swirl in smooth circular motions until clear. Never vortex or shake vigorously, as high-shear agitation can shear peptide bonds and induce protein foaming.

5. Aliquoting Strategy: For extended testing protocols, divide reconstituted liquid into sterile, single-use microcentrifuge tubes under aseptic conditions to prevent atmospheric oxidation and eliminate repeated freeze-thaw cycles.

Batch Quality Documentation & Traceability: Every production lot of CJC-1295 No DAC 5mg (10 vials/kit) undergoes third-party analytical testing. High-Performance Liquid Chromatography (HPLC) chromatograms confirm component purity exceeding 99.0%, while Electrospray Ionization Mass Spectrometry (ESI-MS) confirms precise theoretical molecular mass. Each shipment includes a batch-specific Certificate of Analysis (COA) documenting chemical purity, residual solvent analysis, heavy metal screens, and bacterial endotoxin levels (<0.05 EU/mg) to satisfy institutional compliance requirements.

Strict Regulatory & Research Compliance Statement: CJC-1295 No DAC 5mg (10 vials/kit) is produced, packaged, and distributed exclusively for in vitro laboratory research, academic experimentation, chemical synthesis, and preclinical research. CJC-1295 No DAC 5mg (10 vials/kit) is strictly not intended, formulated, or approved for human or animal consumption, therapeutic medical treatment, clinical diagnostic work, or cosmetic applications. All handling must be conducted by certified research personnel operating within equipped laboratory facilities in compliance with OSHA workplace safety regulations and institutional biosafety protocols.